Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal Oniris

Home page

Epidemiological modelling and its use to manage COVID-19

Insights into mechanistic models, by the DYNAMO team

Over the next few weeks, we will present some key elements of epidemiological modelling through short educational articles. These articles will help you to better understand and decipher the assumptions underlying the epidemiological models that are currently widely used, and how these assumptions can impact predictions regarding the spread of pathogens, particularly SARS-CoV-2. The objective is to discover the advantages and limitations of mechanistic modelling, an approach that is at the core of the DYNAMO team's work. The examples of models will be inspired by models used in crisis, but sometimes simplified to make them accessible.

#7 – If my test is positive, what does that mean?

Let's step outside of modeling for a moment to discuss an important question in epidemiology: what exactly does the result of a screening test mean?

A test is characterized by its sensitivity (Se) and specificity (Sp). The sensitivity of a test is its ability to give a positive result when an infected individual is tested (although one must know for sure that he or she is infected). The specificity of a test is its ability to give a negative result when an uninfected individual is tested (again, one must be sure that the individual is not infected). To determine the Se and Sp values of a test, experimental work is needed to compare the results given by this test with those obtained with another test with well-known characteristics (usually a gold standard).

However, when you go for a test, you do not know in advance what your health status is since you are trying to determine it. Once the test done, what is the probability of actually being infected when the test is positive? What is the probability of being truly uninfected when the test is negative? To find out, you have to calculate the positive (PPV) and negative (NPV) predictive values of the test. We must therefore know not only the characteristics of the test (Se and Sp), but also a third key information: the prevalence of infection p in the population which the tested indidivual belongs, i.e. the proportion of people who are actually infected in this population. This gives the following table:

Infected individuals

Non-infected individuals

Positive test

True positives (VP) = Se x p

False positives (FP) = (1-Sp) x (1-p)

Negative test 

False negatives (FN) = (1-Se) x p

True negatives (VN) = Sp x (1-p)

The predictive values can be calculated as follows:

VPP = VP / (VP+FP) = Se x p / (Se x p + (1-Sp) x (1-p))

VPN = VN / (VN+FN) = Sp x (1-p) / (Sp x (1-p) + (1-Se) x p)

Let's take as an example a large population like France (70 million inhabitants), where 10% of the people are tested (7 million). Let us imagine that the prevalence of infection is p=1%, and that the test has a sensitivity Se=90% and a specificity Sp=98%. The table gives:

Infected

Non-infected

Positive test

63 000 VP

138 600 FP

Negative test

7 000 FN

6 794 400 VN

Applying the above formulas to calculate the predictive values, we find that a person with a positive test result has a 31% chance (PPV) of actually being infected (and a 69% chance of not being infected). A person with a negative result has a 99.9% chance (NPV) of being truly uninfected. Other examples are shown in the figure below. The negative predictive value is very good when the prevalence is low, while the positive predictive value is less good, but allows the right precautions to be taken.

Valeurs prédictives négatives (tiret) et positives (continu) pour 2 jeux de valeurs de sensibilité et spécificité

Positive (VPP) and negative (VPN) predictive values of the test according to its sensitivity (in blue: Se=0.9; in black: Se=0.5), specificity (in blue: Sp=0.99; in black: Sp=0.98) and the prevalence of infection.

To sum up: tests do of course play a key role in controlling an epidemic, as they help to identify infected and uninfected individuals, but their use is not that simple. The uncertainty resulting from their sensitivity, specificity and prevalence of infection (which, remember, varies over time) must be taken into account in order to make a relevant use of their results.